BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H3: BRII-196/BRII-198)
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
This PHASE3 trial investigates COVID-19 and is currently completed. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jun 2024 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2023 — Mar 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jun 2023 [monthly]
Completed PHASE3
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Brii Biosciences Limited
- Cardiothoracic Surgical Trials Network
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
- Kirby Institute
- Medical Research Council
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Prevention and Early Treatment of Acute Lung Injury
- US Department of Veterans Affairs
- University of Copenhagen
- University of Minnesota
- Washington D.C. Veterans Affairs Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .